CoChat

Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis

Open access
Zheng, Tongsen, Wang, Jiabei, Zhao, Yuhan, Zhang, Cen, Lin, Meihua, Wang, Xiaowen, Yu, Haiyang, Liu, Lianxin, Feng, Zhaohui, Hu, Wenwei · 2013 · Nature Communications
Cited by 108

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

The tumour suppressor p53 is frequently mutated in tumours. Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF). Mutp53 can accumulate to high levels in tumours, which promotes mutp53 GOF in tumorigenesis. The mechanism of mutp53 accumulation is poorly understood. Here we find that MDM2 isoforms promote mutp53 accumulation in tumours. MDM2 isoform B (MDM2-B), the MDM2 isoform most frequently over-expressed in human tumours, interacts with full-length MDM2 to inhibit MDM2-mediated mutp53 degradation, promoting mutp53 accumulation and GOF in tumorigenesis. Furthermore, MDM2-B overexpression correlates with mutp53 accumulation in human tumours. In mutp53 knock-in mice, a MDM2 isoform similar to human MDM2-B is overexpressed in the majority of tumours, which promotes mutp53 accumulation and tumorigenesis. Thus, overexpression of MDM2 isoforms promotes mutp53 accumulation in tumours, contributing to mutp53 GOF in tumorigenesis. This may be an important mechanism by which MDM2 isoforms promote tumorigenesis. Mdm2 controls the levels of the tumour suppressor p53 in cells and p53 is often mutated in cancer. Here, Zheng et al. show that a particular Mdm2 isoform that is altered in cancer leads to elevated levels of mutant p53 protein and enhanced gain-of-function of the protein.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms3996

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 27

  1. Levine, A. J., Hu, W. & Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027–1036 (2006). · DOI · Paper page
  2. Blandino, G., Levine, A. J. & Oren, M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477–485 (1999). · DOI · Paper page
  3. Midgley, C. A. & Lane, D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15, 1179–1189 (1997). · DOI · Paper page
  4. Terzian, T. et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337–1344 (2008). · DOI · Paper page
  5. Bartel, F. et al. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 95, 168–175 (2001). · DOI · Paper page
  6. Matsumoto, R. et al. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58, 609–613 (1998).
  7. Bartel, F., Harris, L. C., Wurl, P. & Taubert, H. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. Mol. Cancer Res. 2, 29–35 (2004). · DOI · Paper page
  8. Bartel, F., Taubert, H. & Harris, L. C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2, 9–15 (2002). · DOI · Paper page
  9. Fridman, J. S. et al. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res. 63, 5703–5706 (2003).
  10. Schuster, K., Fan, L. & Harris, L. C. MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol. Cancer Res. 5, 403–412 (2007). · DOI
  11. Evans, S. C. et al. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20, 4041–4049 (2001). · DOI
  12. Dang, J. et al. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62, 1222–1230 (2002).
  13. Cheng, Q. et al. Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol. Cell Biol. 31, 4951–4963 (2011). · DOI · Paper page
  14. Duan, W., Gao, L., Jin, D., Otterson, G. A. & Villalona-Calero, M. A. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Res. 17, 355–366 (2008). · DOI
  15. Scian, M. J. et al. Modulation of gene expression by tumour-derived p53 mutants. Cancer Res. 64, 7447–7454 (2004). · DOI · Paper page
  16. Adorno, M. et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87–98 (2009). · DOI · Paper page
  17. Strano, S. et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503–29512 (2000). · DOI · Paper page
  18. Liu, J. et al. TAp63gamma enhances nucleotide excision repair through transcriptional regulation of DNA repair genes. DNA Repair (Amst.) 11, 167–176 (2012). · DOI
  19. Di Como, C. J., Gaiddon, C. & Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell Biol. 19, 1438–1449 (1999). · DOI · Paper page
  20. Chandler, D. S., Singh, R. K., Caldwell, L. C., Bitler, J. L. & Lozano, G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 66, 9502–9508 (2006). · DOI · Paper page
  21. Muller, P., Hrstka, R., Coomber, D., Lane, D. P. & Vojtesek, B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27, 3371–3383 (2008). · DOI · Paper page
  22. Esser, C., Scheffner, M. & Hohfeld, J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280, 27443–27448 (2005). · DOI · Paper page
  23. Li, D. et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 9, 577–588 (2011). · DOI · Paper page
  24. Suh, Y. A. et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 71, 7168–7175 (2011). · DOI · Paper page
  25. Harvey, D. M. & Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375–2385 (1991). · DOI · Paper page
  26. Chen, J., Marechal, V. & Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107–4114 (1993). · DOI · Paper page
  27. Hu, W. et al. Gene Amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1, 360–368 (2010). · DOI

Cited by

See all 108

Metadata

Authors
Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W.
Venue
Nature Communications
Published
2013-12-20
Volume
4
Issue
1
Pages
2996-2996
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2094042239
Cited by
108
References
15
FWCI
4.90
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. https://app.cochat.ai/papers/10.1038/ncomms3996
The paper
Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W. (2013). Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nature Communications. https://doi.org/10.1038/ncomms3996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.